Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
4,712,245
-
Total 13F shares
-
118,946
-
Share change
-
-22,607
-
Total reported value
-
$47,579
-
Price per share
-
$0.40
-
Number of holders
-
9
-
Value change
-
-$11,403
-
Number of buys
-
5
-
Number of sells
-
4
Institutional Holders of Entero Therapeutics, Inc. - Common stock, par value $0.0001 per share (ENTO) as of Q2 2025
As of 30 Jun 2025,
Entero Therapeutics, Inc. - Common stock, par value $0.0001 per share (ENTO) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
118,946 shares.
The largest 9 holders included
GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, TWO SIGMA SECURITIES, LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., and BANK OF AMERICA CORP /DE/.
This page lists
9
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.